Hemophilias and Other Disorders of Hemostasis

Emery and Rimoin's Principles and Practice of Medical Genetics

Volumn , Issue , 2013, Pages 1-33

  Shavit, Jordan A ^a   Ginsburg, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882749214     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-383834-6.00077-X     Document Type: Chapter

References (253)

1. R.W. Colman, et al. (2001) Overview of Hemostasis. R.W. Colman, et al., (Eds) Hemostasis and Thrombosis Basic Principles and Clinical Practice Philadelphia: Lippincott Williams & Wilkins 3-20.
2. N.S. Jenny and K.G. Mann (2003) Coagulation Cascade: An Overview. J. Loscalzo, A.I. Schafer (Eds) Thrombosis and Hemorrhage Philadelphia: Lippincott Williams & Wilkins 1-21.
3. O.D. Ratnoff (1991) Evolution of Knowledge About Hemostasis. O.D. Ratnoff, C.D. Forbes (Eds) Disorders of Hemostasis Philadelphia: W. B. Saunders Company 1-17.
4. D. Gailani and G.J. Broze Jr. (1991) Factor XI Activation in a Revised Model of Blood Coagulation. Science 253 909-912.
5. K. Naito and K. Fujikawa (1991) Activation of Human Blood Coagulation Factor XI Independent of Factor XII. Factor XI Is Activated by Thrombin and Factor XIa in the Presence of Negatively Charged Surfaces. J. Biol. Chem. 266 7353-7358.
6. M. Hoffman and D.M. Monroe 3rd. (2001) A Cell-Based Model of Hemostasis. Thromb. Haemost. 85(6), 958-965.
7. S.E. Lind (1991) The Bleeding Time Does Not Predict Surgical Bleeding. Blood 77 2547-2552.
8. T. Quiroga, et al. (2004) Template Bleeding Time and PFA-100 Have Low Sensitivity to Screen Patients with Hereditary Mucocutaneous Hemorrhages: Comparative Study in 148 Patients. J. Thromb. Haemost. 2(6), 892-898.
9. G.I. Ingram (1976) The History of Haemophilia. J. Clin. Pathol. 29 469-479.
10. L.W. Hoyer (1994) Hemophilia A. N. Engl. J. Med. 330 38-47.
11. B. Furie, S.A. Limentani and C.G. Rosenfield (1994) A Practical Guide to the Evaluation and Treatment of Hemophilia. Blood 84 3-9.
12. R.F. Stevens (1999) The History of Haemophilia in the Royal Families of Europe. Br. J. Haematol. 105(1), 25-32.
13. E.I. Rogaev, et al. (2009) Genotype Analysis Identifies the Cause of the “Royal Disease”. Science 326(5954), 817.
14. P.K. Jones and O.D. Ratnoff (1991) The Changing Prognosis of Classic Hemophilia (Factor VIII “Deficiency”). Ann. Intern. Med. 114 641-648.
15. P.M. Mannucci and E.G.D. Tuddenham (2001) Medical Progress—The Hemophilias—From Royal Genes to Gene Therapy. N. Engl. J. Med. 344(23), 1773-1779.
16. J. Gitschier, et al. (1984) Characterization of the Human Factor VIII Gene. Nature 312 326-330.
17. R.J. Kaufman (1992) Biological Regulation of Factor VIII Activity. Ann. Rev. Med. 43 325-339.
18. J.J. Toole, et al. (1984) Molecular Cloning of a cDNA Encoding Human Antihaemophilic Factor. Nature 312 342-347.
19. G.A. Vehar, et al. (1984) Structure of Human Factor VIII. Nature 312 337-342.
20. G.A.F. Nicolaes and B. Dahlback (2002) Factor V and Thrombotic Disease—Description of a Janus-Faced Protein. Arterioscl. Thromb. Vasc. Biol. 22(4), 530-538.
21. D.L. Eaton, et al. (1986) Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule. Biochemistry 25 8343-8347.
22. D.D. Pittman, K.A. Marquette and R.J. Kaufman (1994) Role of the B-Domain for Factor VIII and Factor V Expression and Function. Blood 84 4214-4225.
23. J.J. Toole, et al. (1986) A Large Region (~95 kDa) of Human Factor VIII Is Dispensable for In Vitro Procoagulant Activity. Proc. Nat. Acad. Sci. U.S.A 83 5939-5942.
24. S.E. Antonarakis, H.H. Kazazian Jr. and E.G.D. Tuddenham (1995) Molecular Etiology of Factor VIII Deficiency in Hemophilia A. Hum. Mutat. 5 1-22.
25. G. Kemball-Cook and E.G.D. Tuddenham (1997) The Factor VIII Mutation Database on the World Wide Web: The Haemophilia A Mutation, Search, Test and Resource Site. HAMSTeRS Update (Version 3.0). Nucleic Acids Res. 25(1), 128-132.
26. B.A. Dombroski, et al. (1991) Isolation of an Active Human Transposable Element. Science 254 1805-1808.
27. H.H. Kazazian Jr., et al. (1988) Hemophilia A Resulting from De Novo Insertion of L1 Sequences Represents a Novel Mechanism for Mutation in Man. Nature 332 164-166.
28. J.A. Naylor, et al. (1992) Factor VIII Gene Explains All Cases of Haemophilia A. Lancet 340 1066-1067.
29. D. Lakich, et al. (1993) Inversions Disrupting the Factor VIII Gene Are a Common Cause of Severe Haemophilia A. Nat. Genet. 5 236-241.
30. S.E. Antonarakis, et al. (1995) Factor VIII Gene Inversions in Severe Hemophilia A: Results of an International Consortium Study. Blood 86(6), 2206-2212.
31. R.D. Bagnall, et al. (2002) Recurrent Inversion Breaking Intron 1 of the Factor VIII Gene Is a Frequent Cause of Severe Hemophilia A. Blood 99(1), 168-174.
32. J. Oldenburg, et al. (2004) Environmental and Genetic Factors Influencing Inhibitor Development. Seminars in Hematology 41(1 Suppl. 1), 82-88.
33. S.C. Gouw and H.M. van den Berg (2009) The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment. Semin. Thromb. Hemost. 35(8), 723-734.
34. K.R. Viel, et al. (2009) Inhibitors of Factor VIII in Black Patients with Hemophilia. N. Engl. J. Med. 360(16), 1618-1627.
35. G.G. Brownlee and C. Rizza (1984) Clotting Factor VIII Cloned. Nature 312 307. 307
36. W.I. Wood, et al. (1984) Expression of Active Human Factor VIII from Recombinant DNA clones. Nature 312 330-337.
37. A. Azzi, et al. (2001) TT Virus Contaminates First-Generation Recombinant Factor VIII Concentrates. Blood 98(8), 2571-2573.
38. B. Mei, et al. (2010) Rational Design of a Fully Active, Long-Acting PEGylated Factor VIII for Hemophilia A Treatment. Blood 116(2), 270-279.
39. H. Ostergaard, et al. (2011) Prolonged Half-Life and Preserved Enzymatic Properties of Factor IX Selectively PEGylated on Native N-Glycans in the Activation Peptide. Blood 118(8), 2333-2341.
40. M. Franchini and G. Lippi (2010) von Willebrand Factor-Containing Factor VIII Concentrates and Inhibitors in Haemophilia A. A Critical Literature Review. Thromb. Haemost. 104(5), 931-940.
41. I.M. Nilsson, et al. (1992) Twenty-Five Years’ Experience of Prophylactic Treatment in Severe Haemophilia A and B. J. Int. Med. 232 25-32.
42. M.J. Manco-Johnson, et al. (2007) Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. N. Engl. J. Med. 357(6), 535-544.
43. P.M. Mannucci (1997) Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years. Blood 90 2515-2521.
44. H.R. Roberts, D.M. Monroe and G.C. White (2004) The Use of Recombinant Factor VIIa in the Treatment of Bleeding Disorders. Blood 104(13), 3858-3864.
45. E.K. Waters, et al. (2011) Aptamer ARC19499 Mediates a Procoagulant Hemostatic Effect by Inhibiting Tissue Factor Pathway Inhibitor. Blood 117(20), 5514-5522.
46. D. Verma, et al. (2010) Oral Delivery of Bioencapsulated Coagulation Factor IX Prevents Inhibitor Formation and Fatal Anaphylaxis in Hemophilia B Mice. Proc. Natl. Acad. Sci. U.S.A 107(15), 7101-7106.
47. H.M. Blau and M.L. Springer (1995) Gene Therapy—A Novel Form of Drug Delivery. N. Engl. J. Med. 333 1204-1207.
48. A.C. Nathwani, A.M. Davidoff and D.C. Linch (2005) A Review of Gene Therapy for Haematological Disorders. Br. J. Haematol. 128(1), 3-17.
49. K.A. High (2011) Gene Therapy for Haemophilia: A Long and Winding Road. J. Thromb. Haemost. 9(Suppl 1), 2-11.
50. A.C. Nathwani, et al. (2011) Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B. N. Engl. J. Med. 365(25), 2357-2365.
51. J.P. Rossiter, et al. (1994) Factor VIII Gene Inversions Causing Severe Hemophilia A Originate Almost Exclusively in Male Germ Cells. Hum. Mol. Genet. 3 1035-1039.
52. M. Leuer, et al. (2001) Somatic Mosaicism in Hemophilia A: A Fairly Common Event. Am. J. Hum. Genet. 69(1), 75-87.
53. G.J. Broze Jr. (2001) Protein Z-Dependent Regulation of Coagulation. Thromb. Haemost. 86(1), 8-13.
54. E. Briët, et al. (1982) Hemophilia B Leyden: A Sex-Linked Hereditary Disorder That Improves after Puberty. N. Engl. J. Med. 306 788-790.
55. M. Crossley, et al. (1992) Recovery from Hemophilia B Leyden: An Androgen-Responsive Element in the Factor IX Promoter. Science 257 377-379.
56. S. Kurachi, et al. (1999) Genetic Mechanisms of Age Regulation of Human Blood Coagulation Factor IX. Science 285(5428), 739-743.
57. D.D. Koeberl, et al. (1990) Mutations Causing Hemophilia B: Direct Estimate of the Underlying Rates of Spontaneous Germ-Line Transitions, Transversions, and Deletions in a Human Gene. Am. J. Hum. Genet. 47 202-217.
58. F. Giannelli, T. Anagnostopoulos and P.M. Green (1999) Mutation Rates in Humans. II. Sporadic Mutation-Specific Rates and Rate of Detrimental Human Mutations Inferred from Hemophilia B. Am. J. Hum. Genet. 65(6), 1580-1587.
59. H. Li, et al. (2011) In Vivo Genome Editing Restores Haemostasis in a Mouse Model of Haemophilia. Nature 475(7355), 217-221.
60. W.L. Nichols, et al. (2008) von Willebrand Disease (VWD): Evidence-Based Diagnosis and Management Guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel Report (USA). Haemophilia 14(2), 171-232.
61. W.C. Nichols, et al. (2003) von Willebrand Disease. J. Loscalzo, A.I. Schafer (Eds) Thrombosis and Hemorrhage Philadelphia: Lipincott Williams & Wilkins 539-559.
62. W.C. Nichols and D. Ginsburg (1997) von Willebrand Disease. Medicine 76 1-20.
63. P.M. Mannucci (2004) Treatment of von Willebrand’s Disease. N. Engl. J. Med. 351(7), 683-694.
64. Z.M. Ruggeri, J. Ware and D. Ginsburg (2003) von Willebrand Factor. J. Loscalzo, A.I. Schafer (Eds) Thrombosis and Hemorrhage Philadelphia, PA: Lippincott Williams & Wilkins 246-265.
65. R. Karger, et al. (2007) Diagnostic Performance of the Platelet Function Analyzer (PFA-100) for the Detection of Disorders of Primary Haemostasis in Patients with a Bleeding History—A Systematic Review and Meta-Analysis. Platelets 18(4), 249-260.
66. P.D. James, et al. (2007) Challenges in Defining Type 2M von Willebrand Disease: Results from a Canadian Cohort Study. J. Thromb. Haemost. 5(9), 1914-1922.
67. C. Mazurier and D. Meyer (1996) Factor VIII Binding Assay of von Willebrand Factor and the Diagnosis of Type 2N von Willebrand Disease—Results of an International Survey. On Behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb. Haemostasis 76 270-274.
68. J.E. Sadler (1998) Biochemistry and Genetics of von Willebrand Factor. Annu. Rev. Biochem. 67 395-424.
69. K.L. Mohlke, et al. (1996) A Common frameshift Mutation in von Willebrand Factor Does Not Alter mRNA Stability but Interferes with Normal Propeptide Processing. Br. J. Haematol. 95 184-191.
70. Z.P. Zhang, et al. (1993) Mutations of von Willebrand Factor Gene in Families with von Willebrand Disease in the Aland Islands. Proc. Natl. Acad. Sci. U.S.A 90 7937-7940.
71. P.D. James, et al. (2007) The Mutational Spectrum of Type 1 von Willebrand Disease: Results from a Canadian Cohort Study. Blood 109(1), 145-154.
72. A. Goodeve, et al. (2007) Phenotype and Genotype of a Cohort of Families Historically Diagnosed with Type 1 von Willebrand Disease in the European Study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 109(1), 112-121.
73. A. Cumming, et al. (2006) An Investigation of the von Willebrand Factor Genotype in UK Patients Diagnosed to Have Type 1 von Willebrand Disease. Thromb. Haemost. 96(5), 630-641.
74. A. Goodeve (2007) Genetics of Type 1 von Willebrand Disease. Curr. Opin. Hematol. 14(5), 444-449.
75. S.E. Lyons, et al. (1992) Impaired Intracellular Transport Produced by a Subset of Type IIA von Willebrand Disease Mutations. J. Biol. Chem. 267 4424-4430.
76. H.M. Tsai, et al. (1997) Proteolytic Cleavage of Recombinant Type 2A von Willebrand Factor Mutants R834W and R834Q: Inhibition by Doxycycline and by Monoclonal Antibody VP-1. Blood 89 1954-1962.
77. K. Fujikawa, et al. (2001) Purification of Human von Willebrand Factor-Cleaving Protease and Its Identification as a New Member of the Metalloproteinase Family. Blood 98(6), 1662-1666.
78. M. Furlan, et al. (1998) von Willebrand Factor-Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome. N. Engl. J. Med. 339(22), 1578-1584.
79. H.E. Gerritsen, et al. (2001) Partial Amino Acid Sequence of Purified von Willebrand Factor-Cleaving Protease. Blood 98(6), 1654-1661.
80. G.G. Levy, D.G. Motto and D. Ginsburg (2005) ADAMTS13 Turns 3. Blood 106(1), 11-17.
81. G.G. Levy, et al. (2001) Mutations in a Member of the ADAMTS Gene Family Cause Thrombotic Thrombocytopenic Purpura. Nature 413 488-494.
82. K. Soejima, et al. (2001) A Novel Human Metalloprotease Synthesized in the Liver and Secreted into the Blood: Possibly, the von Willebrand Factor-Cleaving Protease? J. Biochem. 130(4), 475-480.
83. H.M. Tsai and E.C.Y. Lian (1998) Antibodies to von Willebrand Factor-Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura. N. Engl. J. Med. 339(22), 1585-1594.
84. A.C. Goodeve (2010) The Genetic Basis of von Willebrand Disease. Blood Rev. 24(3), 123-134.
85. E.W. Murray, A.R. Giles and D. Lillicrap (1992) Germ-Line Mosaicism for a Valine-to-Methionine Substitution at Residue 553 in the Glycoprotein Ib-Binding Domain of von Willebrand Factor, Causing Type IIB von Willebrand Disease. Am. J. Hum. Genet. 50 199-207.
86. L. Badimon, et al. (1993) von Willebrand Factor and Cardiovascular Disease. Thromb. Haemost. 70 111-118.
87. I. Guella, et al. (2011) Common Variants in the Haemostatic Gene Pathway Contribute to Risk of Early-Onset Myocardial Infarction in the Italian Population. Thromb. Haemost. 106(4)
88. I. Martinelli (2005) von Willebrand Factor and Factor VIII as Risk Factors for Arterial and Venous Thrombosis. Semin Hematol. 42(1), 49-55.
89. U.M. Vischer (2006) von Willebrand Factor, Endothelial Dysfunction, and Cardiovascular Disease. J. Thromb. Haemost. 4(6), 1186-1193.
90. C.H. Miller, et al. (1979) Genetics of Classic von Willebrand’s Disease. I. Phenotypic Variation within Families. Blood 54 117-145.
91. J.C. Gill, et al. (1987) The Effect of ABO Blood Group on the Diagnosis of von Willebrand Disease. Blood 69 1691-1695.
92. J.C. Souto, et al. (2003) Genome-Wide Linkage Analysis of von Willebrand Factor Plasma Levels: Results from the GAIT Project. Thromb. Haemost. 89(3), 468-474.
93. P.W. Collins, et al. (2008) Type 1 von Willebrand Disease: Application of Emerging Data to Clinical Practice. Haemophilia 14(4), 685-696.
94. K.L. Mohlke, et al. (1999) MVWF, a Dominant Modifier of Murine von Willebrand Factor, Results from Altered Lineage-Specific Expression of a Glycosyltransferase. Cell 96 111-120.
95. D. Ginsburg (2005) Identifying Novel Genetic Determinants of Hemostatic Balance. J. Thromb. Haemost. 3(8), 1561-1568.
96. H.L. Lemmerhirt, et al. (2007) Genetic Regulation of Plasma von Willebrand Factor Levels: Quantitative Trait Loci Analysis in a Mouse Model. J. Thromb. Haemost. 5(2), 329-335.
97. H.L. Lemmerhirt, et al. (2006) Enhanced VWF Biosynthesis and Elevated Plasma VWF Due to a Natural Variant in the Murine VWF Gene. Blood 108(9), 3061-3067.
98. J.A. Shavit, et al. (2009) Modifiers of von Willebrand Factor Identified by Natural Variation in Inbred Strains of Mice. Blood 114(26), 5368-5374.
99. G. Antoni, et al. (2011) Combined Analysis of Three Genome-Wide Association Studies on vWF and FVIII Plasma Levels. BMC Med. Genet. 12 102.
100. N.L. Smith, et al. (2010) Novel Associations of Multiple Genetic Loci with Plasma Levels of Factor VII, Factor VIII, and von Willebrand Factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 121(12), 1382-1392.
101. F. Rodeghiero, G. Castaman and E. Dini (1987) Epidemiological Investigation of the Prevalence of von Willebrand’s Disease. Blood 69 454-459.
102. E.J. Werner, et al. (1993) Prevalence of von Willebrand Disease in Children: A Multiethnic Study. J. Pediatr. 123 893-898.
103. J.E. Sadler (2003) von Willebrand Disease Type 1: A Diagnosis in Search of a Disease. Blood 101(6), 2089-2093.
104. M. Bowman, et al. (2010) The Prevalence of Symptomatic von Willebrand Disease in Primary Care Practice. J. Thromb. Haemost. 8(1), 213-216.
105. M. Bowman, et al. (2010) A Prospective Evaluation of the Prevalence of Symptomatic von Willebrand Disease (VWD) in a Pediatric Primary Care Population. Pediatr. Blood Cancer 55(1), 171-173.
106. E.H. Rose and L.M. Aledort (1991) Nasal Spray Desmopressin (DDAVP) for Mild Hemophilia A and von Willebrand Disease. Ann. Intern. Med. 114 563-568.
107. P.L. Turecek, et al. (2010) Structure and Function of a Recombinant von Willebrand Factor Drug Candidate. Semin Thromb. Hemost. 36(5), 510-521.
108. I.R. Peake, et al. (1990) Family Studies and Prenatal Diagnosis in Severe von Willebrand Disease by Polymerase Chain Reaction Amplification of a Variable Number Tandem Repeat Region of the von Willebrand Factor Gene. Blood 76 555-561.
109. M. Othman (2011) Platelet-Type von Willebrand Disease: Three Decades in the Life of a Rare Bleeding Disorder. Blood Rev. 25(4), 147-153.
110. J.L. Miller (1996) Platelet-Type von Willebrand Disease. Thromb. Haemost. 75(6), 865-869.
111. M. Murata, et al. (1993) Expression of the Phenotypic Abnormality of Platelet-Type von Willebrand Disease in a Recombinant Glycoprotein Ibà Fragment. J. Clin. Invest. 91 2133-2137.
112. P.N. Walsh (1992) Factor XI: A Renaissance. Semin. Hematol. 29 189-201.
113. R. Asakai, et al. (1989) Factor XI (Plasma Thromboplastin Antecedent) Deficiency in Ashkenazi Jews Is a Bleeding Disorder That Can Result from Three Types of Point Mutations. Proc. Natl. Acad. Sci. U.S.A 86 7667-7671.
114. H. Peretz, et al. (1997) The Two Common Mutations Causing Factor XI Deficiency in Jews Stem from Distinct Founders: One of Ancient Middle Eastern Origin and Another of More Recent European Origin. Blood 90(7), 2654-2659.
115. O. Salomon and U. Seligsohn (2004) New Observations on Factor XI Deficiency. Haemophilia 10(Suppl. 4), 184-187.
116. M. de Haan, et al. (1988) Noonan Syndrome: Partial Factor XI Deficiency. Am. J. Med. Genet. 29 277-282.
117. T. Koster, et al. (1994) John Hageman’s Factor and Deep-Vein Thrombosis: Leiden Thrombophilia Study. Br. J. Haematol. 87 422-424.
118. M. Neerman-Arbez, et al. (2000) Mutations in the Fibrinogen Aà Gene Account for the Majority of Cases of Congenital Afibrinogenemia. Blood 96(1), 149-152.
119. H.R. Roberts and M.A. Escobar (2003) Other Coagulation Factor Deficiencies. J. Loscalzo, A.I. Schafer (Eds) Thrombosis and Hemorrhage Baltimore: Lippincott Williams & Wilkins 575-599.
120. M.J. Manco-Johnson, et al. (2009) Pharmacokinetics and Safety of Fibrinogen Concentrate. J. Thromb. Haemost. 7(12), 2064-2069.
121. L. Muszbek, et al. (2011) Novel Aspects of Factor XIII Deficiency. Curr. Opin. Hematol. 18(5), 366-372.
122. P.M. Mannucci, S. Duga and F. Peyvandi (2004) Recessively Inherited Coagulation Disorders. Blood 104(5), 1243-1252.
123. S. Lancellotti and R. De Cristofaro (2009) Congenital Prothrombin Deficiency. Semin. Thromb. Hemost. 35(4), 367-381.
124. W.Y. Sun, et al. (1998) Prothrombin Deficiency Results in Embryonic and Neonatal Lethality in Mice. Proc. Natl. Acad. Sci. U.S.A 95 7597-7602.
125. J. Xue, et al. (1998) Incomplete Embryonic Lethality and Fatal Neonatal Hemorrhage Caused by Prothrombin Deficiency in Mice. Proc. Natl. Acad. Sci. U.S.A 95 7603-7607.
126. P.B. Tracy and K.G. Mann (1987) Abnormal Formation of the Prothrombinase Complex: Factor V Deficiency and Related Disorders. Human Pathol. 18 162-169.
127. R. Asselta and F. Peyvandi (2009) Factor V Deficiency. Semin. Thromb. Hemost. 35(4), 382-389.
128. P.B. Tracy, et al. (1984) Factor V (Quebec): A Bleeding Diathesis Associated with a Qualitative Platelet Factor V Deficiency. J. Clin. Invest. 74 1221-1228.
129. C.M. Janeway, et al. (1996) Factor V Quebec Revisited. Blood 87(9), 3571-3578.
130. W.H. Kahr, et al. (2001) Platelets from Patients with the Quebec Platelet Disorder Contain and Secrete Abnormal Amounts of Urokinase-Type Plasminogen Activator. Blood 98(2), 257-265.
131. A.D. Paterson, et al. (2010) Persons with Quebec Platelet Disorder Have a Tandem Duplication of PLAU, the Urokinase Plasminogen Activator Gene. Blood 115(6), 1264-1266.
132. J.F. Guasch, et al. (1998) Severe Coagulation Factor V Deficiency Caused by a 4 bp Deletion in the Factor V Gene. Br. J. Haematol. 101(1), 32-39.
133. J. Cui, et al. (1996) Fatal Haemorrhage and Incomplete Block to Embryogenesis in Mice Lacking Coagulation Factor V. Nature 384 66-68.
134. T.L. Yang, et al. (2000) Rescue of Fatal Neonatal Hemorrhage in Factor V Deficient Mice by Low Level Transgene Expression. Thromb. Haemost. 83 70-77.
135. H. Sun, et al. (2003) The Murine Platelet and Plasma Factor V Pools Are Biosynthetically Distinct and Sufficient for Minimal Hemostasis. Blood 102 2856-2861.
136. G. Mariani and F. Bernardi (2009) Factor VII Deficiency. Semin. Thromb. Hemost. 35(4), 400-406.
137. M. Menegatti and F. Peyvandi (2009) Factor X Deficiency. Semin. Thromb. Hemost. 35(4), 407-415.
138. B. Zhang and D. Ginsburg (2004) Familial Multiple Coagulation Factor Deficiencies: New Biologic Insight from Rare Genetic Bleeding Disorders. J. Thromb. Haemost. 2 1564-1572.
139. B. Brenner, et al. (1998) A Missense Mutation in Gamma-Glutamyl Carboxylase Gene Causes Combined Deficiency of All Vitamin K-Dependent Blood Coagulation Factors. Blood 92(12), 4554-4559.
140. S. Rost, et al. (2004) Mutations in VKORC1 Cause Warfarin Resistance and Multiple Coagulation Factor Deficiency Type 2. Nature 427(6974), 537-541.
141. T. Li, et al. (2004) Identification of the Gene for Vitamin K Epoxide Reductase. Nature 427(6974), 541-544.
142. M.J. Rieder, et al. (2005) Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose. N. Engl. J. Med. 352(22), 2285-2293.
143. L. Wang, H.L. McLeod and R.M. Weinshilboum (2011) Genomics and Drug Response. N. Engl. J. Med. 364(12), 1144-1153.
144. I.Y. Gong, et al. (2011) Prospective Evaluation of a Pharmacogenetics-Guided Warfarin Loading and Maintenance Dose Regimen for Initiation of Therapy. Blood 118(11), 3163-3171.
145. P. Lenzini, et al. (2010) Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing. Clin. Pharmacol. Ther. 87(5), 572-578.
146. M.H. Rosove and W.W. Grody (2009) Should We Be Applying Warfarin Pharmacogenetics to Clinical Practice? No, Not Now. Ann. Intern. Med. 151(4), 270-273. W95
147. U. Seligsohn, A. Zivelin and E. Zwang (1982) Combined Factor V and Factor VIII Deficiency among Non-Ashkenazi Jews. N. Engl. J. Med. 307 1191-1195.
148. W.C. Nichols, et al. (1998) Mutations in the ER-Golgi Intermediate Compartment Protein ERGIC-53 Cause Combined Deficiency of Coagulation Factors V and VIII. Cell 93 61-70.
149. B. Zhang, et al. (2003) Bleeding Due to Disruption of a Cargo-Specific ER to Golgi Transport Complex. Nat. Genet. 34(2), 220-225.
150. W. Li, et al. (2004) Murine Hermansky–Pudlak Syndrome Genes: Regulators of Lysosome-Related Organelles. Bioessays 26(6), 616-628.
151. R.A. White, et al. (1992) The Murine Pallid Mutation Is a Platelet Storage Pool Disease Associated with the Protein 4.2 (Pallidin) Gene. Nat. Genet. 2 80-83.
152. J.A. Lopez, et al. (1998) Bernard–Soulier Syndrome. Blood 91(12), 4397-4418.
153. A.T. Nurden (1999) Inherited Abnormalities of Platelets. Thromb. Haemost. 82(2), 468-480.
154. B.S. Coller, et al. (1994) Glanzmann Thrombasthenia: New Insights from an Historical Perspective. Semin. Hematol. 31 301-311.
155. P.F. Bray (1994) Inherited Diseases of Platelet Glycoproteins: Considerations for Rapid Molecular Characterization. Thromb. Haemost. 72 492-502.
156. W.H. Kahr, et al. (2011) Mutations in NBEAL2, Encoding a BEACH Protein, Cause Gray Platelet Syndrome. Nat. Genet. 43(8), 738-740.
157. M. Gunay-Aygun, et al. (2011) NBEAL2 Is Mutated in Gray Platelet Syndrome and Is Required for Biogenesis of Platelet Alpha-Granules. Nat. Genet. 43(8), 732-734.
158. C.A. Albers, et al. (2011) Exome Sequencing Identifies NBEAL2 as the Causative Gene for Gray Platelet Syndrome. Nat. Genet. 43(8), 735-737.
159. M.P. Lambert, M. Poncz (2009) Inherited Platelet Disorders. S.H. Orkin, et al., (Eds) Nathan and Oski’s Hematology of Infancy and Childhood 1463-1486.
160. M.S. Turner, et al. (2007) Clinical Impact of Selective Serotonin Reuptake Inhibitors Therapy with Bleeding Risks. J. Intern. Med. 261(3), 205-213.
161. D. Ginsburg (2001) Disorders of the Fibrinolytic System. C.R. Scriver, et al., (Eds) The Metabolic and Molecular Bases of Inherited Disease New York: McGraw Hill 4505-4516.
162. N. Aoki, et al. (1979) Congenital Deficiency of à 2 -Plasmin Inhibitor Associated with Severe Hemorrhagic Tendency. J. Clin. Invest. 63 877-884.
163. W.E. Holmes, et al. (1987) A 2-Antiplasmin Enschede: Alanine Insertion and Abolition of Plasmin Inhibitory Activity. Science 238 209-211.
164. W.P. Fay, et al. (1997) Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred with a Null Mutation in the PAI-1 Gene. Blood 90 204-208.
165. W.P. Fay, et al. (1992) Complete Deficiency of Plasminogen-Activator Inhibitor Type 1 Due to a Frame-Shift Mutation. N. Engl. J. Med. 327 1729-1733.
166. N. Aoki (1989) Hemostasis Associated with Abnormalities of Fibrinolysis. Blood Rev. 3 11-17.
167. M.C. Iannuzzi, et al. (1991) Analysis of the Relationship of von Willebrand Disease (vWD) and Hereditary Hemorrhagic Telangiectasia and Identification of a Potential Type IIA vWD Mutation (IIe865 to Thr). Am. J. Hum. Genet. 48 757-763.
168. M.C. Owen, et al. (1983) Mutation of Antitrypsin to Antithrombin: Alpha1-Antitrypsin Pittsburgh (358 Met-Arg), a Fatal Bleeding Disorder. N. Engl. J. Med. 309 694-698.
169. D. Vidaud, et al. (1992) Met 358 to Arg Mutation of Alpha 1 -Antitrypsin Associated with Protein C Deficiency in a Patient with Mild Bleeding Tendency. J. Clin. Invest. 89 1537-1543.
170. K.A. Bauer (2003) Inherited and Acquired Hypercoagulable States. J. Loscalzo, A.I. Schafer (Eds) Thrombosis and Hemorrhage Baltimore: Lippincott Williams & Wilkins 648-684.
171. J. Malm, et al. (1992) Thromboembolic Disease—Critical Evaluation of Laboratory Investigation. Thromb. Haemost. 68(1), 7-13.
172. B. Dahlback (2008) Advances in Understanding Pathogenic Mechanisms of Thrombophilic Disorders. Blood 112(1), 19-27.
173. M.A. Crowther and J.G. Kelton (2003) Congenital Thrombophilic States Associated with Venous Thrombosis: A Qualitative Overview and Proposed Classification System. Ann. Intern. Med. 138(2), 128-134.
174. M.M. Patnaik and S. Moll (2008) Inherited Antithrombin Deficiency: A Review. Haemophilia 14(6), 1229-1239.
175. C. Demers, et al. (1992) Thrombosis in Antithrombin-III-Deficient Persons. Ann. Intern. Med. 116 754-761.
176. B.J. Sanson, et al. (1999) The Incidence of Venous Thromboembolism in Asymptomatic Carriers of a Deficiency of Antithrombin, Protein C, or Protein S: A Prospective Cohort Study. Blood 94(11), 3702-3706.
177. H.H. Van Boven, et al. (1999) Gene–Gene and Gene–Environment Interactions Determine Risk of Thrombosis in Families with Inherited Antithrombin Deficiency. Blood 94(8), 2590-2594.
178. H.H. Van Boven, et al. (1997) Mortality and Causes of Death in Inherited Antithrombin Deficiency. Thromb. Haemost. 77 452-455.
179. C. Kearon, M. Crowther and J. Hirsh (2000) Management of Patients with Hereditary Hypercoagulable Disorders. Annu. Rev. Med. 51 169-185.
180. J.W. Eikelboom and J.I. Weitz (2010) New Anticoagulants. Circulation 121(13), 1523-1532.
181. J.H. Griffin, et al. (1981) Deficiency of Protein C in Congenital Thrombotic Disease. J. Clin. Invest. 68 1370-1373.
182. T. Koster, et al. (1995) Protein C Deficiency in a Controlled Series of Unselected Outpatients: An Infrequent but Clear Risk Factor for Venous Thrombosis (Leiden Thrombophilia Study). Blood 85 2756-2761.
183. J. Miletich, L. Sherman and G.J. Broze Jr. (1987) Absence of Thrombosis in Subjects with Heterozygous Protein C Deficiency. N. Engl. J. Med. 317 991-996.
184. P.H. Reitsma, et al. (1995) Protein C Deficiency: A Database of Mutations. 1995 Update: On Behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb. Haemost. 73 876-889.
185. M. Makris, et al. (2000) Genetic Analysis, Phenotypic Diagnosis, and Risk of Venous Thrombosis in Families with Inherited Deficiencies of Protein S. Blood 95(6), 1935-1941.
186. R.L. Nachman and R. Silverstein (1993) Hypercoagulable States. Ann. Intern. Med. 119 819-827.
187. B. Dahlback (1995) Inherited Thrombophilia: Resistance to Activated Protein C as a Pathogenic Factor of Venous Thromboembolism. Blood 85(3), 607-614.
188. B. Dahlback, M. Carlsson and P.J. Svensson (1993) Familial Thrombophilia Due to a Previously Unrecognized Mechanism Characterized by Poor Anticoagulant Response to Activated Protein C: Prediction of a Cofactor to Activated Protein C. Proc. Natl. Acad. Sci. U.S.A 90(3), 1004-1008.
189. R.M. Bertina, et al. (1994) Mutation in Blood Coagulation Factor V Associated with Resistance to Activated Protein C. Nature 369 64-67.
190. W.P. Chan, et al. (1998) A Novel Mutation of Arg306 of Factor V Gene in Hong Kong Chinese. Blood 91(4), 1135-1139.
191. D. Williamson, et al. (1998) Factor V Cambridge: A New Mutation (Arg 306 -->Thr) Associated with Resistance to Activated Protein C. Blood 91(4), 1140-1144.
192. K. Amano, et al. (1998) Mutation at Either Arg336 or Arg562 in Factor VIII Is Insufficient for Complete Resistance to Activated Protein C (APC)-Mediated Inactivation: Implications for the APC Resistance Test. Thromb. Haemost. 79(3), 557-563.
193. A. Zivelin, et al. (1997) A Single Genetic Origin for a Common Caucasian Risk Factor for Venous Thrombosis. Blood 89 397-402.
194. D.C. Rees, M. Cox and J.B. Clegg (1995) World Distribution of Factor V Leiden. Lancet 346(8983), 1133-1134.
195. F.R. Rosendaal, et al. (1995) High Risk of Thrombosis in Patients Homozygous for Factor V Leiden (Activated Protein C Resistance). Blood 85(6), 1504-1508.
196. J.A. Heit, et al. (2005) The Incidence of Venous Thromboembolism among Factor V Leiden Carriers: A Community-Based Cohort Study. J. Thromb. Haemost. 3(2), 305-311.
197. K. Juul, et al. (2004) Factor V Leiden and the Risk for Venous Thromboembolism in the Adult Danish Population. Ann. Intern. Med. 140(5), 330-337.
198. J.P. Vandenbroucke, et al. (1994) Increased Risk of Venous Thrombosis in Oral-Contraceptive Users Who Are Carriers of Factor V Leiden Mutation. Lancet 344 1453-1457.
199. M.J. Kupferminc, et al. (1999) Increased Frequency of Genetic Thrombophilia in Women with Complications of Pregnancy. N. Engl. J. Med. 1(340), 9-13.
200. A. Gerhardt, et al. (2000) Prothrombin and Factor V Mutations in Women with a History of Thrombosis during Pregnancy and the Puerperium. N. Engl. J. Med. 342(6), 374-380.
201. D. Dizon-Townson, et al. (2005) The Relationship of the Factor V Leiden Mutation and Pregnancy Outcomes for Mother and Fetus. Obstet. Gynecol. 106(3), 517-524.
202. E.M. Battinelli and K.A. Bauer (2011) Thrombophilias in Pregnancy. Hematol. Oncol. Clin. North. Am. 25(2), 323-333. viii
203. S.M. Bates, et al. (2012) VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl), e691S-e736S.
204. P.M. Ridker, et al. (1995) Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men. N. Engl. J. Med. 332 912-917.
205. E.T.M. Hille, et al. (1997) Mortality and Causes of Death in Families with the Factor V Leiden Mutation (Resistance to Activated Protein C). Blood 89 1963-1967.
206. C. Kearon, et al. (2008) Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl), 45445S-45545S.
207. S. Middeldorp and A. van Hylckama Vlieg (2008) Does Thrombophilia Testing Help in the Clinical Management of Patients? Br. J. Haematol. 143(3), 321-335.
208. K.A. Bauer (2004) Role of Thrombophilia in Deciding on the Duration of Anticoagulation. Semin. Thromb. Hemost. 30(6), 633-637.
209. W.M. Lijfering, et al. (2010) Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A. Circulation 121(15), 1706-1712.
210. P. Brill-Edwards, et al. (2000) Safety of Withholding Heparin in Pregnant Women with a History of Venous Thromboembolism. N. Engl. J. Med. 20 1439-1444.
211. U. Seligsohn and A. Lubetsky (2001) Medical Progress: Genetic Susceptibility to Venous Thrombosis. N. Engl. J. Med. 344(16), 1222-1231.
212. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2011) Recommendations from the EGAPP Working Group: Routine Testing for Factor V Leiden (R506Q) and Prothrombin (20210G>A) Mutations in Adults with a History of Idiopathic Venous Thromboembolism and Their Adult Family Members. Genet. Med. 13(1), 67-76.
213. B.A. Kerlin, et al. (2003) Survival Advantage Associated with Heterozygous Factor V Leiden Mutation in Patients with Severe Sepsis and in Mouse Endotoxemia. Blood 102(9), 3085-3092.
214. P.G. Lindqvist, et al. (1998) Factor V Q 506 Mutation (Activated Protein C Resistance) Associated with Reduced Intrapartum Blood Loss—A Possible Evolutionary Selection Mechanism. Thromb. Haemost. 79(1), 69-73.
215. I. Martinelli, et al. (2007) Type and Location of Venous Thromboembolism in Patients with Factor V Leiden or Prothrombin G20210A and in Those with No Thrombophilia. J. Thromb. Haemost. 5(1), 98-101.
216. H. Bounameaux (2000) Factor V Leiden Paradox: Risk of Deep-Vein Thrombosis but Not of Pulmonary Embolism. Lancet 356(9225), 182-183.
217. S.R. Poort, et al. (1996) A Common Genetic Variation in the 3′-Untranslated Region of the Prothrombin Gene Is Associated with Elevated Plasma Prothrombin Levels and an Increase in Venous Thrombosis. Blood 88 3698-3703.
218. N.H. Gehring, et al. (2001) Increased Efficiency of mRNA 3′ End Formation: A New Genetic Mechanism Contributing to Hereditary Thrombophilia. Nat. Genet. 28(4), 389-392.
219. N. von Ahsen and M. Oellerich (2004) The Intronic Prothrombin 19911A>G Polymorphism Influences Splicing Efficiency and Modulates Effects of the 20210G>A Polymorphism on mRNA Amount and Expression in a Stable Reporter Gene Assay System. Blood 103(2), 586-593.
220. F.R. Rosendaal, et al. (1997) A Common Prothrombin Variant (20210 G to A) Increases the Risk of Myocardial Infarction in Young Women. Blood 90 1747-1750.
221. J.C.M. Meijers, et al. (2000) High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis. N. Engl. J. Med. 342(10), 696-701.
222. H.V. Van, et al. (2000) High Levels of Factor IX Increase the Risk of Venous Thrombosis. Blood 95(12), 3678-3682.
223. P. Simioni, et al. (2009) X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua). N. Engl. J. Med. 361(17), 1671-1675.
224. F.R. Rosendaal (2000) High Levels of Factor VIII and Venous Thrombosis. Thromb. Haemost. 83(1), 1-2.
225. P.A. Kyrle, et al. (2000) High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism. N. Engl. J. Med. 343(7), 457-462.
226. R.A. Kraaijenhagen, et al. (2000) High Plasma Concentration of Factor VIII Is a Major Risk Factor for Venous Thromboembolism. Thromb. Haemost. 83(1), 5-9.
227. J. O’Donnell, et al. (2000) Elevation of FVIII: C in Venous Thromboembolism Is Persistent and Independent of the Acute Phase Response. Thromb. Haemost. 83(1), 10-13.
228. M. Berger, et al. (2005) High Factor VIII Levels in Venous Thromboembolism Show Linkage to Imprinted Loci on Chromosomes 5 and 11. Blood 105(2), 638-644.
229. H. Mandel, et al. (1996) Coexistence of Hereditary Homocystinuria and Factor V Leiden—Effect on Thrombosis. N. Engl. J. Med. 334 763-768.
230. G.N. Welch and J. Loscalzo (1998) Homocysteine and Antherothrombosis. N. Engl. J. Med. 338(15), 1042-1050.
231. M. den Heijer, et al. (1996) Hyperhomocysteinemia as a Risk Factor for Deep-Vein Thrombosis. N. Engl. J. Med. 334 759-762.
232. M. den Heijer, et al. (2007) Homocysteine Lowering by B Vitamins and the Secondary Prevention of Deep Vein Thrombosis and Pulmonary Embolism: A Randomized, Placebo-Controlled, Double-Blind Trial. Blood 109(1), 139-144.
233. E. Lonn (2007) Homocysteine in the Prevention of Ischemic Heart Disease, Stroke and Venous Thromboembolism: Therapeutic Target or Just Another Distraction? Curr. Opin. Hematol. 14(5), 481-487.
234. A. D’Angelo and J. Selhub (1997) Homocysteine and Thrombotic Disease. Blood 90 1-11.
235. J. Frederiksen, et al. (2004) Methylenetetrahydrofolate Reductase Polymorphism (C677T), Hyperhomocysteinemia, and Risk of Ischemic Cardiovascular Disease and Venous Thromboembolism: Prospective and Case-Control Studies from the Copenhagen City Heart Study. Blood 104(10), 3046-3051.
236. I.D. Bezemer, et al. (2007) No Association between the Common MTHFR 677C->T Polymorphism and Venous Thrombosis: Results from the MEGA Study. Arch. Intern. Med. 167(5), 497-501.
237. L.A.J. Kluijtmans, et al. (1998) Thermolabile Methylenetetrahydrofolate Reductase and Factor V Leiden in the Risk of Deep-Vein Thrombosis. Thromb. Haemost. 79(2), 254-258.
238. M.B. Keijzer, et al. (2007) No Interaction Between Factor V Leiden and Hyperhomocysteinemia or MTHFR 677TT Genotype in Venous Thrombosis. Results of a Meta-Analysis of Published Studies and a Large Case-Only Study. Thromb. Haemost. 97(1), 32-37.
239. N. Aoki, et al. (1978) Abnormal Plasminogen. A Hereditary Molecular Abnormality Found in a Patient with Recurrent Thrombosis. J. Clin. Invest. 61 1186-1195.
240. F. Demarmels Biasiutti, et al. (1998) Is Plasminogen Deficiency a Thrombotic Risk Factor? A Study on 23 Thrombophilic Patients and Their Family Members. Thromb. Haemost. 80(1), 167-170.
241. R.C. Tait, et al. (1996) Isolated Familial Plasminogen Deficiency May Not Be a Risk Factor for Thrombosis. Thromb. Haemost. 76 1004-1008.
242. T.H. Bugge, et al. (1995) Plasminogen Deficiency Causes Severe Thrombosis but Is Compatible with Development and Reproduction. Genes Dev. 9 794-807.
243. V.A. Ploplis, et al. (1995) Effects of Disruption of the Plasminogen Gene on Thrombosis, Growth, and Health in Mice. Circulation 92 2585-2593.
244. V. Schuster, et al. (1997) Homozygous Mutations in the Plasminogen Gene of Two Unrelated Girls with Ligneous Conjunctivitis. Blood 90 958-966.
245. V. Schuster, et al. (1999) Compound-Heterozygous Mutations in the Plasminogen Gene Predispose to the Development of Ligneous Conjunctivitis. Blood 93(10), 3457-3466.
246. D. Schott, et al. (1998) Therapy with a Purified Plasminogen Concentrate in an Infant with Ligneous Conjunctivitis and Homozygous Plasminogen Deficiency. N. Engl. J. Med. 339(23), 1679-1686.
247. A.F. Drew, et al. (1998) Ligneous Conjunctivitis in Plasminogen-Deficient Mice. Blood 91(5), 1616-1624.
248. J.L. Moake (2002) Thrombotic Microangiopathies. N. Engl. J. Med. 347(8), 589-600.
249. J.N. George (2000) How I Treat Patients with Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome. Blood 96(4), 1223-1229.
250. B.P.C. Koeleman, et al. (1994) Activated Protein C Resistance as an Additional Risk Factor for Thrombosis in Protein C-Deficient Families. Blood 84(4), 1031-1035.
251. B.P.C. Koeleman, et al. (1995) Factor V Leiden: An Additional Risk Factor for Thrombosis in Protein S Deficient Families? Thromb. Haemost. 74(2), 580-583.
252. S.D. Berkowitz, Z.M. Ruggeri and T.S. Zimmerman (1989) von Willebrand Disease. T.S. Zimmerman, Z.M. Ruggeri (Eds) Coagulation and Bleeding Disorders. The Role of Factor VIII and von Willebrand Factor New York: Marcel Dekker, Inc. 215-259.
253. D. Ginsburg and E.J.W. Bowie (1992) Molecular Genetics of von Willebrand Disease. Blood 79 2507-2519.